India's only CDSCO Class A registered, NABL lab tested protective helmet for epilepsy and elderly fall-risk patients. Trusted by 100+ families across 15+ cities.
Protecting the People
Who Matter Most to You
Absorbed
The Helmet
They Will Actually Wear.
- ✓CDSCO Class A Medical Device — Reg. No. MFG/Class A-NSNM/2026/028112
- ✓NABL tested 88.1% impact attenuation — independently verified by Cotecna India
- ✓139g–148g ultralight — no neck strain, safe for all-day and sleep wear
- ✓Skin safe certified — pH 6.7, heavy metals BDL, safe from age 5+
- ✓Free size exchange — personal sizing call with every single order
100% of Families
Recommend DazzleSafe™
"My sister has been saved multiple times from head injury during falls. She has been using the same unit for over 2 years and it has never failed her. First of its kind in India."
"My 85-year-old mother wears it for long hours and is happy to wear it. The design is so much better than anything we tried before. Will definitely recommend it."
"The fit is very comfortable. It has been extremely useful in daily life. On a scale of 1 to 5, I rate the comfort as a 5. A reassuring balance of comfort and protection."
No Other Helmet in India
Has All of This
| Feature | 🛡️ DazzleSafe™ | Others |
|---|---|---|
| CDSCO Class A | ✅ Registered | ❌ Not registered |
| NABL Lab Tested | ✅ 88.1% impact | ❌ Self-certified |
| Weight | ✅ 139g–148g | ❌ 300–600g |
| Skin Safety Tested | ✅ pH 6.7, safe | ❌ No data |
| Daily Wear Comfort | ✅ 62.5% voluntary | ❌ Often abandoned |
| Price | ✅ ₹1,999 | ❌ ₹3,000–₹15,000 |
Invisible Protection. Visible Confidence.
India's only CDSCO Class A registered, NABL lab tested epilepsy helmet. 139g–148g. Trusted by 100+ families across 15+ cities. Free shipping. COD available. Ships in 24 hours.
🛡️ Order DazzleSafe™ — ₹1,999
Who is DazzleSafe for?
DazzleSafe™ — An Innovation by Neurocare Technology Pvt. Ltd. Clinically-aligned protective headgear for epilepsy and elderly fall protection.
2026 Roadmap: From Innovation to Global Impact
DazzleSafe™ is currently advancing from observational pilot data toward international clinical validation. Our objective is to bridge the gap between institutional-grade engineering and global safety benchmarks, ensuring that non-stigmatizing protection is accessible to the 50 million people living with epilepsy worldwide.
US Infrastructure: Identifying North American distribution and logistics partners to support 24-hour delivery for US patients.
